Data from the BRCAAway Study Confirms Better PFS & Efficacy with a Combination of Olaparib + Abiraterone Prednisone

In this MEDtalk, Dr. Maha Hussain presents data from the BRCAAway study. The study demonstrates that combining abiraterone & prednisone with olaparib improves efficacy and progression-free survival in metastatic castration-resistant prostate cancer patients with BRCA1/2 or ATM mutation.